Medicine and Dentistry
Migraine
96%
Transformed Migraine
25%
Headache
24%
Symptom
19%
Women's Health
17%
Episodic Migraine
12%
Pain Catastrophizing
11%
Post-Hoc Analysis
11%
Disease
11%
Menstrual Cycle
7%
Menstrual Migraine
7%
Prevalence
7%
Sex Hormone
6%
Obesity
6%
Observational Study
6%
Galcanezumab
6%
Pregnanediol
6%
Glucuronide
6%
Urinary System
6%
Diet Quality
5%
Randomized Controlled Trial
5%
Allodynia
5%
Placebo
5%
Clinical Pain
5%
Catastrophizing
5%
Lasmiditan
5%
Cardiovascular Disease
5%
Sleep Disorder
5%
Psychological Aspect
5%
Apoplexy
5%
Lifestyle Intervention
5%
Luteinizing Hormone
5%
Obstructive Sleep Apnea
5%
Contraceptive Agent
5%
Contraindication
5%
Cohort Effect
5%
Immunocytochemistry
5%
Glucosylceramidase
5%
Follitropin
5%
Lung Parenchyma
5%
Treatment Effect
5%
Ecological Momentary Assessment
5%
Systematic Review
5%
Mixture Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Headache
42%
Symptom
21%
Transformed Migraine
16%
Episodic Migraine
16%
Disease
13%
Menstrual Migraine
12%
Pregnanediol
12%
Glucuronide
12%
Prevalence
11%
Placebo
8%
Luteinizing Hormone
7%
Follitropin
7%
Sleep Disorder
7%
Galcanezumab
6%
Erenumab
6%
Obesity
6%
Sex Hormone
5%
Triptan Derivative
5%
Contraceptive Agent
5%
Phorbol Ester
5%
Lasmiditan
5%
Sleep Disordered Breathing
5%
Cardiovascular Disease
5%
Perimenopause
5%
Side Effect
5%
Electron Microscopy
5%
Mixture Model
5%
Inflammation
5%
Surfactant
5%
Pharmacotherapy
5%
Receptor Antagonist
5%
Keyphrases
Migraine
39%
Headache
25%
Migraine without Aura (MWoA)
10%
Pain Catastrophizing
10%
Migraine Prevention
10%
Obesity
10%
Pain Acceptance
10%
Migraine Attack
10%
Menopause
9%
Monthly Migraine Days
8%
Migraine Days
8%
Chronic Migraine
8%
Menstrual Cycle
8%
Overweight or Obesity
7%
Perimenstrual
7%
Migraine Frequency
6%
Menstruation
5%
Comorbid
5%
Headache-related Disability
5%
Serum Hormones
5%
Glucocerebrosidase mutations
5%
Cutaneous Allodynia
5%
Clinical Pain
5%
Reproductive Aging
5%
Catastrophizing
5%
Luteal
5%
Scoping Literature Review
5%
SPA1
5%
SPA2
5%
Medical Groups
5%
Transition Studies
5%
Treatment Effect
5%
Patient Expectations
5%
Longitudinal Relations
5%
Fetal Lung
5%
Perimenopause
5%
Preventive Migraine Treatment
5%
Intractable Headache
5%
B-regions
5%
Sex-related
5%
Frequency Consistency
5%
Surfactant Protein A (SP-A)
5%
Sleep Quality
5%
Pattern Quality
5%
Dietary Intake Patterns
5%
Prevalence Study
5%
Naturalistic Assessment
5%
Motor Function
5%
Mutation Carriers
5%
Cognitive Functioning
5%